Cargando…

Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies

Advancement in the understanding of cancer development in recent years has identified epigenetic abnormalities as a common factor in both tumorigenesis and refractory disease. One such event is the dysregulation of histone deacetylases (HDACs) in both hematological and solid tumors, and has conseque...

Descripción completa

Detalles Bibliográficos
Autores principales: Ellis, Leigh, Pili, Roberto
Formato: Texto
Lenguaje:English
Publicado: MDPI 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3000686/
https://www.ncbi.nlm.nih.gov/pubmed/21151768
http://dx.doi.org/10.3390/ph3082441
_version_ 1782193560285609984
author Ellis, Leigh
Pili, Roberto
author_facet Ellis, Leigh
Pili, Roberto
author_sort Ellis, Leigh
collection PubMed
description Advancement in the understanding of cancer development in recent years has identified epigenetic abnormalities as a common factor in both tumorigenesis and refractory disease. One such event is the dysregulation of histone deacetylases (HDACs) in both hematological and solid tumors, and has consequently resulted in the development of HDAC inhibitors (HDACI) to overcome this. HDACI exhibit pleiotropic biological effects including inhibition of angiogenesis and the induction of autophagy and apoptosis. Although HDACI exhibit modest results as single agents in preclinical and clinical data, they often fall short, and therefore HDACI are most promising in combinational strategies with either standard treatments or with other experimental chemotherapies and targeted therapies. This review will discuss the induction of autophagy and apoptosis and the inhibition of angiogenesis by HDACI, and also pre-clinical and clinical combination strategies using these agents.
format Text
id pubmed-3000686
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-30006862010-12-10 Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies Ellis, Leigh Pili, Roberto Pharmaceuticals (Basel) Review Advancement in the understanding of cancer development in recent years has identified epigenetic abnormalities as a common factor in both tumorigenesis and refractory disease. One such event is the dysregulation of histone deacetylases (HDACs) in both hematological and solid tumors, and has consequently resulted in the development of HDAC inhibitors (HDACI) to overcome this. HDACI exhibit pleiotropic biological effects including inhibition of angiogenesis and the induction of autophagy and apoptosis. Although HDACI exhibit modest results as single agents in preclinical and clinical data, they often fall short, and therefore HDACI are most promising in combinational strategies with either standard treatments or with other experimental chemotherapies and targeted therapies. This review will discuss the induction of autophagy and apoptosis and the inhibition of angiogenesis by HDACI, and also pre-clinical and clinical combination strategies using these agents. MDPI 2010-08-04 /pmc/articles/PMC3000686/ /pubmed/21151768 http://dx.doi.org/10.3390/ph3082441 Text en © 2010 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an Open Access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Ellis, Leigh
Pili, Roberto
Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies
title Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies
title_full Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies
title_fullStr Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies
title_full_unstemmed Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies
title_short Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies
title_sort histone deacetylase inhibitors: advancing therapeutic strategies in hematological and solid malignancies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3000686/
https://www.ncbi.nlm.nih.gov/pubmed/21151768
http://dx.doi.org/10.3390/ph3082441
work_keys_str_mv AT ellisleigh histonedeacetylaseinhibitorsadvancingtherapeuticstrategiesinhematologicalandsolidmalignancies
AT piliroberto histonedeacetylaseinhibitorsadvancingtherapeuticstrategiesinhematologicalandsolidmalignancies